Trends in ototoxicity monitoring among cisplatin-treated patients with cancer
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE: This study aims to characterize patterns in ototoxicity monitoring and identify potential barriers to audiologic follow-up.
METHODS: We performed a single-institution retrospective cohort study on adult (≥ 18 years old) cancer patients treated with cisplatin from January 2014 to September 2021. Our primary outcomes were rates of baseline and post-treatment audiograms at the following time points: 3, 6, 12, and greater than 12 months. Time-to-event analyses were performed to describe additional insights to ototoxicity monitoring patterns.
RESULTS: Nine hundred fifty-five patients with cancer were included for analysis. The most common primary cancer sites were head and neck (64%), followed by cervical (24%). Three hundred seventy-three patients (39%) underwent baseline audiometric assessment, 38 patients (4%) received audiologic evaluation during chemotherapy, and 346 patients (36%) obtained at least one post-treatment audiogram. Audiologic follow-up was greatest within 3 months of completing chemotherapy (26%), but this tapered dramatically to less than 10% at every other post-treatment time point. Patients with head and neck cancer achieved higher rates of audiologic follow-up at every time point than patients with non-head and neck cancer except for during treatment.
CONCLUSIONS: Ototoxicity monitoring is an inconsistent practice, particularly during chemotherapy and for long-term surveillance of hearing loss. Patients with non-head and neck cancer may be at increased risk for loss of audiologic follow-up.
IMPLICATIONS FOR CANCER SURVIVORS: Cisplatin ototoxicity is a common occurrence that can be effectively managed with auditory rehabilitation. Therefore, referrals to audiology and counseling on treatment-related ototoxicity are recommended throughout chemotherapy and cancer survivorship.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of cancer survivorship : research and practice - (2024) vom: 17. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, David S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 17.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s11764-024-01586-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371194334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371194334 | ||
| 003 | DE-627 | ||
| 005 | 20240417233645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11764-024-01586-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM371194334 | ||
| 035 | |a (NLM)38630333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, David S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in ototoxicity monitoring among cisplatin-treated patients with cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE: This study aims to characterize patterns in ototoxicity monitoring and identify potential barriers to audiologic follow-up | ||
| 520 | |a METHODS: We performed a single-institution retrospective cohort study on adult (≥ 18 years old) cancer patients treated with cisplatin from January 2014 to September 2021. Our primary outcomes were rates of baseline and post-treatment audiograms at the following time points: 3, 6, 12, and greater than 12 months. Time-to-event analyses were performed to describe additional insights to ototoxicity monitoring patterns | ||
| 520 | |a RESULTS: Nine hundred fifty-five patients with cancer were included for analysis. The most common primary cancer sites were head and neck (64%), followed by cervical (24%). Three hundred seventy-three patients (39%) underwent baseline audiometric assessment, 38 patients (4%) received audiologic evaluation during chemotherapy, and 346 patients (36%) obtained at least one post-treatment audiogram. Audiologic follow-up was greatest within 3 months of completing chemotherapy (26%), but this tapered dramatically to less than 10% at every other post-treatment time point. Patients with head and neck cancer achieved higher rates of audiologic follow-up at every time point than patients with non-head and neck cancer except for during treatment | ||
| 520 | |a CONCLUSIONS: Ototoxicity monitoring is an inconsistent practice, particularly during chemotherapy and for long-term surveillance of hearing loss. Patients with non-head and neck cancer may be at increased risk for loss of audiologic follow-up | ||
| 520 | |a IMPLICATIONS FOR CANCER SURVIVORS: Cisplatin ototoxicity is a common occurrence that can be effectively managed with auditory rehabilitation. Therefore, referrals to audiology and counseling on treatment-related ototoxicity are recommended throughout chemotherapy and cancer survivorship | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a Ototoxicity monitoring | |
| 700 | 1 | |a Travis, Emma Y |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Susan K |e verfasserin |4 aut | |
| 700 | 1 | |a Munyemana, Marie-Ange |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Rowling, Cathryn Collopy |e verfasserin |4 aut | |
| 700 | 1 | |a Rich, Jason T |e verfasserin |4 aut | |
| 700 | 1 | |a Pipkorn, Patrik |e verfasserin |4 aut | |
| 700 | 1 | |a Puram, Sidharth V |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Ryan S |e verfasserin |4 aut | |
| 700 | 1 | |a Adkins, Douglas R |e verfasserin |4 aut | |
| 700 | 1 | |a Oppelt, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Thorstad, Wade L |e verfasserin |4 aut | |
| 700 | 1 | |a Wick, Cameron C |e verfasserin |4 aut | |
| 700 | 1 | |a Zevallos, Jose P |e verfasserin |4 aut | |
| 700 | 1 | |a McClannahan, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Mazul, Angela L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer survivorship : research and practice |d 2007 |g (2024) vom: 17. Apr. |w (DE-627)NLM181109514 |x 1932-2267 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:17 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11764-024-01586-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 17 |c 04 | ||